Pharmaceuticals, Biotechnology and Life Sciences
Issuance of U.S. Patent US10835501B2 Begins Development of Indication BioSciences’ Intellectual Patent Portfolio for statin plus cannabinoid combination therapies. SILVERTHORNE,…
Issuance of U.S. Patent US10835501B2 Begins Development of Indication BioSciences’ Intellectual Patent Portfolio for statin plus cannabinoid combination therapies. SILVERTHORNE,…
ATLANTA–(BUSINESS WIRE)–Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with…
T3/C15 enriched cannabis fraction inhibits liver fibrosis Findings add to Can-Fite’s expertise and assets in the treatment of liver disease…
– Revita® DMR, combined with GLP-1RA medication, enables 53% of patients with type 2 diabetes to discontinue and remain off…
– Conference Call Today at 8 a.m. EST to Discuss Transaction – – Provides TEPEZZA® (teprotumumab-trbw) Supply Update; Submitted Prior…
Study showed PNT001 was well-tolerated at dose levels that may provide potential therapeutic effect PNT001 to be evaluated next in…
Study showed PNT001 was well-tolerated at dose levels that may provide potential therapeutic effect PNT001 to be evaluated next in…
– Topline Data Expected in 2H 2021 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments…
Analyst and investor event scheduled for Monday, Feb. 8 at 8:00 a.m. ET Four platform presentations and two posters on…